Therapie primärer Hirntumoren

Aktualisierte Version

Literatur

• 1 Weller M, Wick W. Primäre intrakranielle und spinale Tumoren.  In: Brandt Th, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer, 4. Auflage (im Druck) 2003
• 2 Herrlinger U. Primäre ZNS-Lymphome und ZNS-Manifestationen bei systemischen Lymphomen.  In: Brandt Th, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer, 4. Auflage (im Druck) 2003
• 3 Davis F G, McCarthy B J, Freels S, Kupelian V, Bondy M L. The conditional probability of survival of patients with primary malignant brain tumors. Surveillance, epidemiology, and end results (SEER) data.  Cancer. 1999;  85 485-491
• 4 Surawicz T S, McCarthy B J, Kupelian V, Jukich P J, Bruner J M, Davis F G. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990 - 1994.  Neuro-Oncol. 1999;  1 14-25
• 5 Karnofsky D A, Abelmann W H, Craver L F, Burchenal J M. The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma.  Cancer. 1948;  1 634-656
• 6 Cairncross J G, Ueki K, Zlatescu M C, Lisle D K, Finkelstein D M, Hammond R R. et al . Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.  J Natl Cancer Inst. 1998;  90 1473-1479
• 7 Smith J S, Perry A, Borell T J, Lee H K, O'Fallon J, Hosek S M. et al . Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.  J Clin Oncol. 2000;  18 636-645
• 8 Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K. et al . Effects of ACNU and radiotherapy on malignant glioma.  J Neurosurg. 1986;  64 53-57
• 9 Friedman H S, McLendon R E, Kerby T, Dugan M, Bigner S H, Henry A J. et al . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.  J Clin Oncol. 1998;  16 3851-3857
• 10 Yung W KA, Prados M D, Yaga-Tur R, Rosenfeld S S, Brada M, Friedman H S. et al for the Temodal Brain Tumor Group . Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.  J Clin Oncol. 1999;  17 2762-2771
• 11 Yung W KA, Albright R E, Olson J, Fredericks R, Fink K, Prados M D. et al . A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.  Br J Cancer. 2000;  83 588-593
• 12 Levin V A, Silver P, Hannigan J, Wara W M, Gutin P H, Davis R L, Wilson C B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.  Int J Radiat Oncol Biol Phys. 1990;  18 321-324
• 13 Streffer J, Schabet M, Bamberg M, Grote E H, Meyermann R, Voigt K. et al . A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.  J Neurol. 2000;  247 297-302
• 14 Shaw E G, Wisoff J H. Prospective clinical trials of intracranial low-grade gliomas in adults and children.  Neuro-Oncol. 2003;  5 153-160
• 15 Schrell U M, Rittig M G, Anders M, Koch U H, Marschalek R, Kiesewetter F, Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.  J Neurosurg. 1997;  86 840-844
• 16 Schabet M. Epidemiology of primary CNS lymphoma.  J Neuro-Oncol. 1999;  43 199-201
• 17 Herrlinger U, Schabet M, Brugger W, Kortmann R D, Engel C, Schmeck-Lindenau H J, Mergenthaler H G, Krauseneck P, Benöhr C, Meisner C, Wiestler O D, Dichgans J, Kanz L, Bamberg M, Weller M. for the Neuro-Oncology Working Group (NOA) of the German Cancer Society . German Cancer Society Neuro-Oncology Working Group NOA-03 multi-center trial of single agent high-dose methotrexate for primary CNS lymphoma.  Ann Neurol. 2002;  51 247-252